Cargando…
Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adu...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224858/ https://www.ncbi.nlm.nih.gov/pubmed/27790858 http://dx.doi.org/10.1002/cam4.889 |
_version_ | 1782493433474056192 |
---|---|
author | Lindsay, Julian Kabir, Masrura Gilroy, Nicole Dyer, Gemma Brice, Lisa Moore, John Greenwood, Matthew Hertzberg, Mark Gottlieb, David Larsen, Stephen R. Hogg, Megan Brown, Louisa Huang, Gillian Tan, Jeff Ward, Christopher Kerridge, Ian |
author_facet | Lindsay, Julian Kabir, Masrura Gilroy, Nicole Dyer, Gemma Brice, Lisa Moore, John Greenwood, Matthew Hertzberg, Mark Gottlieb, David Larsen, Stephen R. Hogg, Megan Brown, Louisa Huang, Gillian Tan, Jeff Ward, Christopher Kerridge, Ian |
author_sort | Lindsay, Julian |
collection | PubMed |
description | In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402‐item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipulative and body‐based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population. |
format | Online Article Text |
id | pubmed-5224858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52248582017-01-17 Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia Lindsay, Julian Kabir, Masrura Gilroy, Nicole Dyer, Gemma Brice, Lisa Moore, John Greenwood, Matthew Hertzberg, Mark Gottlieb, David Larsen, Stephen R. Hogg, Megan Brown, Louisa Huang, Gillian Tan, Jeff Ward, Christopher Kerridge, Ian Cancer Med Cancer Prevention In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402‐item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipulative and body‐based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population. John Wiley and Sons Inc. 2016-10-27 /pmc/articles/PMC5224858/ /pubmed/27790858 http://dx.doi.org/10.1002/cam4.889 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Lindsay, Julian Kabir, Masrura Gilroy, Nicole Dyer, Gemma Brice, Lisa Moore, John Greenwood, Matthew Hertzberg, Mark Gottlieb, David Larsen, Stephen R. Hogg, Megan Brown, Louisa Huang, Gillian Tan, Jeff Ward, Christopher Kerridge, Ian Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
title | Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
title_full | Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
title_fullStr | Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
title_full_unstemmed | Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
title_short | Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia |
title_sort | epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in australia |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224858/ https://www.ncbi.nlm.nih.gov/pubmed/27790858 http://dx.doi.org/10.1002/cam4.889 |
work_keys_str_mv | AT lindsayjulian epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT kabirmasrura epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT gilroynicole epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT dyergemma epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT bricelisa epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT moorejohn epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT greenwoodmatthew epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT hertzbergmark epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT gottliebdavid epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT larsenstephenr epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT hoggmegan epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT brownlouisa epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT huanggillian epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT tanjeff epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT wardchristopher epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia AT kerridgeian epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia |